Nelfinavir for anemia in myelofibrosis
Treatments studied
Part of Blood & lymphatic clinical trials.
This study tests whether an old HIV drug, nelfinavir, can help treat anemia (low red blood cells) in people with myelofibrosis. The goal is to help your bone marrow use iron better so you may have more energy and need fewer blood transfusions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with myelofibrosis (a type of bone marrow cancer).
- You are anemic, with a hemoglobin level of 10 g/dL or lower.
- You have enough iron stored (ferritin level of 100 or higher).
- You are not taking momelotinib or pacritinib (specific myelofibrosis drugs).
- You are not pregnant or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether an oral medicine called nuvisertib (TP-3654) can improve symptoms and disease control in people with myelofibrosis, including those who did not respond well to JAK inhibitors. Some participants may also receive nuvisertib with other JAK-related medicines to see which approach works best.
This Phase 1 study tests PegINFa (after a bone marrow transplant) to see if it is safe and can help control myelofibrosis. You must be eligible for transplant and meet specific donor, timing, and health criteria before starting the study drug.
This trial tests an oral medicine called flonoltinib maleate for people with myelofibrosis. It may help reduce an enlarged spleen and improve symptoms like fatigue and night sweats.
This trial tests two new medicines, selinexor and pacritinib, for people with myelofibrosis who have low blood counts and have not yet tried JAK inhibitor therapy. The goal is to see if this combination helps reduce spleen size and improve blood counts.
This trial tests an experimental drug called PMD-026 for people with myelofibrosis that has not responded well to a JAK inhibitor (like ruxolitinib). The goal is to see if PMD-026 can help reduce symptoms and spleen size.
This trial tests a combination of two oral medications for people with myelofibrosis, a type of bone marrow cancer. It may be an option if you have not been helped by standard JAK inhibitor therapy or if you have never tried one.
Hear when a new Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.